CP-481715

CP-481715 is a potent, selective, and orally administered small molecule antagonist of the chemokine receptor CCR1 (C-C chemokine receptor type 1). It was developed by Pfizer as a potential treatment for inflammatory diseases such as rheumatoid arthritis and skin disorders. Mechanistically, it acts as a competitive and reversible antagonist at CCR1, blocking the binding and signaling of its ligands CCL3 and CCL5. This inhibition reduces leukocyte recruitment and inflammatory responses in preclinical models. Despite promising pharmacological properties—including high selectivity for human CCR1—development was discontinued after phase 1 clinical trials for inflammation-related indications[1][2][6].

Other names

quinoxaline-2-carboxylic acid (4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyloctyl)amide212790-31-3